ArticleOncotarget2016

Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells.

Martuza Sarwar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.